GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Policy Acquisition Expense

DNTH (Dianthus Therapeutics) Policy Acquisition Expense


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Dianthus Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.